Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Kloess

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|June 27, 2017
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer TreatmentOlaf Oberschmidt, Stephan Kloess, Ulrike Koehl
Cancers|July 10, 2020
Harnessing NK Cell Checkpoint-Modulating ImmunotherapiesSachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloess
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|June 28, 2019
CAR-Expressing Natural Killer Cells for Cancer RetargetingStephan Kloess, Anna Kretschmer, Lilly Stahl, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 6, 2023
Correction to: Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 25, 2015
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
BMC Cancer|May 3, 2015
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroidsAriane Giannattasio, Sandra Weil, Stephan Kloess, et al.
Nutrition and Cancer|June 25, 2010
Reactive oxygen species abrogate the anticarcinogenic effect of eicosapentaenoic acid in Atm-deficient miceRalf Schubert, Janine Reichenbach, Claudia Koch, et al.
Frontiers in Pharmacology|March 3, 2015
Advantages and applications of CAR-expressing natural killer cellsWolfgang Glienke, Ruth Esser, Christoph Priesner, et al.
Human Gene Therapy Methods|April 19, 2019
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor EngineeringOlaf Oberschmidt, Michael Morgan, Volker Huppert, et al.
Frontiers in Immunology|October 23, 2018
Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK SubsetStephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|June 27, 2017
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer TreatmentOlaf Oberschmidt, Stephan Kloess, Ulrike Koehl
Cancers|July 10, 2020
Harnessing NK Cell Checkpoint-Modulating ImmunotherapiesSachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloess
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|June 28, 2019
CAR-Expressing Natural Killer Cells for Cancer RetargetingStephan Kloess, Anna Kretschmer, Lilly Stahl, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 6, 2023
Correction to: Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 25, 2015
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectorsJulia D Suerth, Michael A Morgan, Stephan Kloess, et al.
BMC Cancer|May 3, 2015
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroidsAriane Giannattasio, Sandra Weil, Stephan Kloess, et al.
Nutrition and Cancer|June 25, 2010
Reactive oxygen species abrogate the anticarcinogenic effect of eicosapentaenoic acid in Atm-deficient miceRalf Schubert, Janine Reichenbach, Claudia Koch, et al.
Frontiers in Pharmacology|March 3, 2015
Advantages and applications of CAR-expressing natural killer cellsWolfgang Glienke, Ruth Esser, Christoph Priesner, et al.
Human Gene Therapy Methods|April 19, 2019
Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor EngineeringOlaf Oberschmidt, Michael Morgan, Volker Huppert, et al.
Frontiers in Immunology|October 23, 2018
Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK SubsetStephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Pageof 3